ASH 2018 Sorteren Publicatiedatum oplopendPublicatiedatum aflopend Filteren ASH 2018 - Peter Hoogerbrugge, PhD, Tisagenlecleucel in Acute Lymphoblastic Leukemia Peter Hoogerbrugge, PhD Pediatric Oncologist, Prinses Maxima Centrum, Utrecht Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young AdultLees meer0219KYM1113236HematologieHematologieALLAndere categorieënASH 2018HematalksOther Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken ASH 2018 Stephan A. Grupp, MD, PhD, Tisagenlecleucel in Acute Lymphoblastic Leukemia Stephan A. Grupp, MD, PhD Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Updated Analysis of the Efficacy andLees meer0219KYM1113236HematologieHematologieALLAndere categorieënASH 2018HematalksOther Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken ASH 2018 - James Baumgardner, PhD, CAR-T Health Outcomes and Competitive Cost-Effectiveness James Baumgardner, PhD Precision Health Economics, Los Angeles, CA CAR-T Therapy Displays Favorable Gains in Health Outcomes and Competitive Cost-Effectiveness WhenLees meer0219KYM1113236HematologieHematologieALLAndere categorieënASH 2018HematalksOther Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken ASH 2018 - Jason R. Gotlib, MD, MS, The New Tool KIT in Advanced Systemic Mastocytosis Jason R. Gotlib, MD, MS Stanford Cancer Institute, Stanford, CA The New Tool KIT in Advanced Systemic Mastocytosis Lees meer1218HEM1089107HematologieAMLASH 2018Andere categorieënHematalks Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken ASH 2018 - Francesco Passamonti, MD, Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly Francesco Passamonti, MD Dipartimento di Medicina e Chirurgia, Università dell'Insubria, Varese, Italy Ruxolitinib for the Treatment of InadequatelyLees meer0119JAK1106215HematologieHematologieASH 2018Andere categorieënHematalks Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken ASH 2018 - Susanne Isfort, Thromboembolic Events worsen QoL Susanne Isfort Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University,Lees meer0119JAK1106222HematologieHematologieASH 2018Andere categorieënMPN Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken ASH 2018 - Ruben Mesa, PhD, MPN and MF study results Ruben Mesa, PhDRuben Mesa PhD UT Health San Antonio Cancer Center, San Antonio Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs.Lees meer0119JAK1106222HematologieHematologieASH 2018Andere categorieënHematalksMPN Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken ASH 2018 - Natasha Szuber, MD, MPN studies Natasha Szuber, MD Division of Hematology, Mayo Clinic, Montreal, QC, Canada Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison ofLees meer0119JAK1106222HematologieHematologieASH 2018Andere categorieënHematalksMPN Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken Alicia Rovó, MD, PhD I-WISH studies Alicia Rovó, MD, PhD Inselspital Universitätspital Bern, Switzerland Review of 2 abstracts related to the I WISH study, in which there was a focus on different aspect of quality of lifeLees meer0119REV1100610HematologieASH 2018HematalksAndere categorieënITP Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken ASH 2018 - Oliver Meyer Oliver Meyer, Institute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in PatientsLees meer0119REV1100610HematologieASH 2018Hematalks Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken Toon meer
ASH 2018 - Peter Hoogerbrugge, PhD, Tisagenlecleucel in Acute Lymphoblastic Leukemia Peter Hoogerbrugge, PhD Pediatric Oncologist, Prinses Maxima Centrum, Utrecht Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young AdultLees meer0219KYM1113236HematologieHematologieALLAndere categorieënASH 2018HematalksOther Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken
ASH 2018 Stephan A. Grupp, MD, PhD, Tisagenlecleucel in Acute Lymphoblastic Leukemia Stephan A. Grupp, MD, PhD Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Updated Analysis of the Efficacy andLees meer0219KYM1113236HematologieHematologieALLAndere categorieënASH 2018HematalksOther Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken
ASH 2018 - James Baumgardner, PhD, CAR-T Health Outcomes and Competitive Cost-Effectiveness James Baumgardner, PhD Precision Health Economics, Los Angeles, CA CAR-T Therapy Displays Favorable Gains in Health Outcomes and Competitive Cost-Effectiveness WhenLees meer0219KYM1113236HematologieHematologieALLAndere categorieënASH 2018HematalksOther Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken
ASH 2018 - Jason R. Gotlib, MD, MS, The New Tool KIT in Advanced Systemic Mastocytosis Jason R. Gotlib, MD, MS Stanford Cancer Institute, Stanford, CA The New Tool KIT in Advanced Systemic Mastocytosis Lees meer1218HEM1089107HematologieAMLASH 2018Andere categorieënHematalks Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken
ASH 2018 - Francesco Passamonti, MD, Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly Francesco Passamonti, MD Dipartimento di Medicina e Chirurgia, Università dell'Insubria, Varese, Italy Ruxolitinib for the Treatment of InadequatelyLees meer0119JAK1106215HematologieHematologieASH 2018Andere categorieënHematalks Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken
ASH 2018 - Susanne Isfort, Thromboembolic Events worsen QoL Susanne Isfort Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University,Lees meer0119JAK1106222HematologieHematologieASH 2018Andere categorieënMPN Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken
ASH 2018 - Ruben Mesa, PhD, MPN and MF study results Ruben Mesa, PhDRuben Mesa PhD UT Health San Antonio Cancer Center, San Antonio Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs.Lees meer0119JAK1106222HematologieHematologieASH 2018Andere categorieënHematalksMPN Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken
ASH 2018 - Natasha Szuber, MD, MPN studies Natasha Szuber, MD Division of Hematology, Mayo Clinic, Montreal, QC, Canada Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison ofLees meer0119JAK1106222HematologieHematologieASH 2018Andere categorieënHematalksMPN Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken
Alicia Rovó, MD, PhD I-WISH studies Alicia Rovó, MD, PhD Inselspital Universitätspital Bern, Switzerland Review of 2 abstracts related to the I WISH study, in which there was a focus on different aspect of quality of lifeLees meer0119REV1100610HematologieASH 2018HematalksAndere categorieënITP Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken
ASH 2018 - Oliver Meyer Oliver Meyer, Institute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in PatientsLees meer0119REV1100610HematologieASH 2018Hematalks Delen Twitter Linkedin Facebook Pinterest Google plus Afdrukken
